Compare General Mills, Inc. (GIS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Twist Bioscience Corp — how do they compare? General Mills, Inc. trades at $32.13 (market cap $17.43B), while Twist Bioscience Corp trades at $161.66 (market cap $10.08B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 7.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Twist Bioscience Corp for 27 Days on average.
| GIS | TWST | |
|---|---|---|
Market Cap | $17.43B | $10.08B |
Volume | 16,554,362 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $205.00 |
52-Week Low | $31.67 | $25.45 |
Typical Hold Time | 106 Days | 27 Days |
Enterprise Value | $30.61B | $10.01B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.77, down 1.27% with bearish technical signals despite beating Q2 2026 EPS estimates. The stock shows attractive valuation metrics with P/E of 9.23 and P/S of 0.96, but faces fundamental challenges including negative net income margin of -4.89% and declining revenue trends from $19.5B in 2025 to projected $18.3B in 2026. Recent CEO transition to Dana McNabb and dividend stability at $0.61 quarterly provide some stability amid operational headwinds.
The outlook remains cautious with Wall Street showing mixed sentiment - 61% hold ratings but $36 consensus target suggests 13% upside. Key risks include ongoing margin pressure, competitive threats in packaged foods, and macroeconomic sensitivity. The high 7% dividend yield offers income appeal but sustainability concerns persist given negative profitability metrics and cash flow challenges.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
